Tacrolimus and posttransplant diabetes mellitus in renal transplantation.
作者： Johannes P. van Hooff , Maarten H. L. Christiaans , Elly M. van Duijnhoven
DOI: 10.1097/01.TP.0000157870.21957.E5
关键词:
摘要: The most prominent side effect of tacrolimus is the induction posttransplant diabetes mellitus (PTDM). In this review, authors discuss incidence, mechanism, prevention, and treatment tacrolimus-induced PTDM in renal patients.
sci-hub.se 参考文章(38)
Joshua Miller, Robert Mendez, John D. Pirsch, Stephen C. Jensik, Safety and efficacy of tacrolimus in combination with mycophenolate mofetil (MMF) in cadaveric renal transplant recipients. FK506/MMF Dose-Ranging Kidney Transplant Study Group Transplantation. ,vol. 69, pp. 875- 880 ,(2000) , 10.1097/00007890-200003150-00035
Johannes M. M. Boots, Maarten H. L. Christiaans, Elly M. van Duijnhoven, Robert-Jan van Suylen, Johannes P. van Hooff, Early steroid withdrawal in renal transplantation with tacrolimus dual therapy: a pilot study Transplantation. ,vol. 74, pp. 1703- 1709 ,(2002) , 10.1097/00007890-200212270-00011
Bertram L. Kasiske, Jon J. Snyder, David Gilbertson, Ajthur J. Matas, Diabetes Mellitus after Kidney Transplantation in the United States American Journal of Transplantation. ,vol. 3, pp. 178- 185 ,(2003) , 10.1034/J.1600-6143.2003.00010.X
KOUCHIT TAMUKA, TAKAO FUJIMURA, TAKESHI TSUTSUMI, KEIKO NAKAMURA, TOSHIKAZU OGAWA, CHIZURU ATLIMARU, YURI HIRANO, KANAME OHARA, KAZUYUKI OHTSUKA, KYOICHI SHIMOMURA, MASAKAZU KOBAYASHI, Transcriptional inhibition of insulin by FK506 and possible involvement of FK506 binding protein-12 in pancreatic beta-cell Transplantation. ,vol. 59, pp. 1606- 1613 ,(1995) , 10.1097/00007890-199506000-00018
Matthew R. Weir, Jeffrey C. Fink, Risk for posttransplant diabetes mellitus with current immunosuppressive medications American Journal of Kidney Diseases. ,vol. 34, pp. 1- 13 ,(1999) , 10.1016/S0272-6386(99)70101-0
G Montagnino, B.K Krämer, M Arias, Efficacy and safety of tacrolimus compared with cyclosporine microemulsion in kidney transplantation: twelve-month follow-up. International Congress on Immunosuppression. ,vol. 34, pp. 1635- 1637 ,(2002) , 10.1016/S0041-1345(02)02960-3
ANDERS LINDHOLM, DAGFINN ALBRECHTSEN, LARS FRÖDIN, GUNNAR TUFVESON, NILS H. PERSSON, GÖRAN LUNDGREN, Ischemic heart disease--major cause of death and graft loss after renal transplantation in Scandinavia. Transplantation. ,vol. 60, pp. 451- 457 ,(1995) , 10.1097/00007890-199509000-00008
Bart D. Maes, Dirk Kuypers, Thierry Messiaen, Pieter Evenepoel, Chantal Mathieu, Willy Coosemans, Jacques Pirenne, Yves F. Ch. Vanrenterghem, Posttransplantation diabetes mellitus in FK-506-treated renal transplant recipients: analysis of incidence and risk factors. Transplantation. ,vol. 72, pp. 1655- 1661 ,(2001) , 10.1097/00007890-200111270-00014
H.P Grewal, J.R Thistlethwaite, G.E Loss, D.S Bruce, C.T Siegel, D.C Cronin, K.A Newell, J.M Millis, E.S Woodle, Corticosteroid cessation 1 week following renal transplantation using tacrolimus/mycophenolate mofetil based immunosuppression. The International Congress on Immunosuppression. ,vol. 30, pp. 1378- 1379 ,(1998) , 10.1016/S0041-1345(98)00281-4
A. David Mayer, Jan Dmitrewski, Jean-Paul Squifflet, Tatjana Besse, Bernd Grabensee, Barbara Klein, Friedrich W. Eigler, Uwe Heemann, Rudolf Pichlmayr, Matthias Behrend, Yves Vanrenterghem, Jan Donck, Johannes van Hooff, Maarten Christiaans, Jose M. Morales, Amado Andres, Robert W.G. Johnson, Colin Short, Bernd Buchholz, Nikola Rehmert, Walter Land, Stefan Schleibner, John L.R. Forsythe, David Talbot, Hans-H. Neumayer, Ingeborg Hauser, Bo-G??ran Ericzon, Christina Brattstr??m, Kerstin Claesson, Ferdinand M??hlbacher, Erich Pohanka, Multicenter randomized trial comparing tacrolimus (FK506) and cyclosporine in the prevention of renal allograft rejection - A report of the European Tacrolimus Multicenter Renal Study Group Transplantation. ,vol. 64, pp. 436- 443 ,(1997) , 10.1097/00007890-199708150-00012